(Total Views: 202)
Posted On: 03/24/2021 3:00:39 PM
Post# of 44968
$NBIO clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.
Screening to enroll patients in the trial is already underway. Those interested may review trial requirements here.
PTB is a natural human antibody that works by binding to Cell surface Vimentin (sometimes referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
Screening to enroll patients in the trial is already underway. Those interested may review trial requirements here.
PTB is a natural human antibody that works by binding to Cell surface Vimentin (sometimes referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
(0)
(0)
